Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients.

Détails

ID Serval
serval:BIB_C8F67FDB86FD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients.
Périodique
Respiration; international review of thoracic diseases
Auteur(s)
Panchaud A., Di Paolo E.R., Koutsokera A., Winterfeld U., Weisskopf E., Baud D., Sauty A., Csajka C.
ISSN
1423-0356 (Electronic)
ISSN-L
0025-7931
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
91
Numéro
4
Pages
333-348
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Health management of cystic fibrosis (CF) patients should be maximized during pregnancy and breastfeeding because of its significant impact on the maternal and newborn outcomes. Thus, numerous drugs will have to be continued during pregnancy and lactation. Most of the drugs representing CF treatment lines cross the placenta or are excreted into human milk. Research addressing the risks and benefits of drugs used in CF patients during pregnancy and lactation is often incomplete or challenged by limited methodology, which often leads to conflicting or inconclusive results. Yet, potential treatment benefits for CF pregnant patients most often outbalance potential risks for the unborn child.

Mots-clé
Breast Feeding, Cystic Fibrosis/drug therapy, Drug-Related Side Effects and Adverse Reactions, Female, Fetus/drug effects, Humans, Pregnancy, Pregnancy Complications/drug therapy, Teratogens
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/06/2016 16:53
Dernière modification de la notice
01/10/2019 11:23
Données d'usage